» Home

  » About

  » Services

  » Speaking

  » Case Studies

  » Publications

       » Papers

       » Patents

       » Presentations / Posters

       » Books
  » Testimonials

  » Blog

  » Media

  » Affiliates and Partners

  » Contact

Published Journal Articles and Book Chapters

Heterobifunctional PEGs: Efficient Synthetic Strategies and Useful Conjugation Methodologies.  Daniel E. Levy; Brian Frederick; Bing Luo; Samuel Zalipsky; Bioorganic and Medicinal Chemistry Letters, 2010, 20, 6823-6826.

PEGylated Iminodiacetic Acid Zinc Complex Stabilizes Cationic RNA-Bearing Nanoparticles.  Daniel E. Levy; Zhongli Ding; Chiwei Hu; Samuel Zalipsky;  Bioorganic and Medicinal Chemistry Letters, 2010, 20, 5499-5501.

Financial Challenges and Shrinking Pipelines.  Daniel E. Levy; European Biopharmaceutical Review, April 2010, 10-13,  Invited Contribution.

Amide-Based Inhibitors of p38a MAP Kinase.  Part 1:  Discovery of Novel N-PyridylAmide Lead Molecules.  Gregory R. Luedtke; Kurt Schinzel; Xuefei Tan; Richland W. Tester; Imad Nashashibi; Yong-jin Xu; Sundeep Dugar; Daniel E. Levy; Joon Jung; Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2556-2559.


Amide-Based Inhibitors of p38
a MAP Kinase.  Part 2:  Design, Synthesis and SAR of Potent N-pyrimidyl Amides.  Richland Tester; Xuefei Tan; Gregory R. Luedtke; Imad Nashashibi; Kurt Schinzel; Weiling Liang; Joon Jung; Sundeep Dugar; Albert Liclican; Jocelyn Tabora; Daniel E. Levy; Steven Do; Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2560-2563.

 

Piperidine-Based Heterocyclic Oxalyl Amides as Potent p38a MAP Kinase Inhibitors.  Babu J. Mavunkel; John J. Perumattam; Xuefei Tan; Gregory R. Luedtke; Qing Lu; Don Lim; Darin Kizer; Sundeep Dugar; Sarvajit Chakravarty; Yong-jin Xu; Joon Jung; Albert Liclican; Daniel E. Levy; Jocelyn Tabora; Bioorganic and Medicinal Chemistry Letters, 2010, 20, 1059-1062.

 

Design and Synthesis of Piperazine-Indole p38a MAP Kinase Inhibitors with Improved Pharmacokinetic Profiles.  Xuefei Tan; Richland W. Tester; Gregory R. Luedtke; Sarvajit Chakravarty; Babu J. Mavunkel; John J. Perumattam; Qing Lu; Imad Nashashibi; Joon Jung; Jie Hu; Albert Liclican; Ramona Almirez; Jocelyn Tabora; Vinh Tran; Maureen Laney; Daniel E. Levy; Sundeep Dugar; Bioorganic and Medicinal Chemistry Letters, 2010, 20, 828-831.


Aryl-Indolyl Maleimides as Inhibitors of CaMKIIδ.  Part 1: SAR of the Aryl Region
.  Daniel E. Levy; Dan-Xiong Wang; Qing Lu; Zheng Chen; John Perumattam; Yong-jin Xu; Albert Liclican; Jeffrey Higaki; Hanmin Dong; Maureen Laney; Babu Mavunkel; Sundeep Dugar; Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2390-2394.

Aryl-Indolyl Maleimides as Inhibitors of CaMKIIδ.  Part 2: SAR of the Amine Tether.  Daniel E. Levy; Dan-Xiong Wang; Qing Lu; Zheng Chen; John Perumattam; Yong-jin Xu; Jeffrey Higaki; Hanmin Dong; Albert Liclican; Maureen Laney; Babu Mavunkel; Sundeep Dugar; Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2395-2398.

Aryl-Indolyl Maleimides as Inhibitors of CaMKIIδ.  Part 3: Importance of the Indole Orientation.  Qing Lu; Zheng Chen; John Perumattam; Dan-Xiong Wang; Weiling Liang; Yong-jin Xu; Steven Do; Llorente Bonaga; Jeffrey Higaki; Hanmin Dong; Albert Liclican; Steve Sideris; Maureen Laney; Sundeep Dugar; Babu Mavunkel; Daniel E. Levy; Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2399-2403.

Pyrimidine-Based Inhibitors of CaMKIIδ.  Babu Mavunkel; Yong-jin Xu; Bindu Goyal; Don Lim; Qing Lu; Zheng Chen; Dan-Xiong Wang; Jeffrey Higaki; Indrani Chakraborty; Albert Liclican; Steve Sideris; Maureen Laney; Ulrike Delling; Rosanne Catalano; Linda S. Higgins; Hui Wang; Jing Wang; Ying Feng; Sundeep Dugar; Daniel E. Levy; Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2404-2408.

Type 2 Diabetes and Alzheimer’s Disease:  From Common Pathologies to Potential new Therapeutics.  Daniel E. Levy; Journal of Diabetes Science and Technology, 2007, 1(4), 590-594.

Functionalization of Sugars.  Daniel E. Levy In The Organic Chemistry of Sugars.  Daniel E. Levy, Ed; Peter Fugedi, Ed; CRC Press:  Boca Raton, FL, 2005, pp 904.

Strategies towards C-Glycosides.  Daniel E. Levy In The Organic Chemistry of Sugars.  Daniel E. Levy, Ed; Peter Fugedi, Ed; CRC Press:  Boca Raton, FL, 2005, pp 904.

Direct Inhibition of Type 5 Adenylyl Cyclase Prevents Myocardial Apoptosis without Functional Deterioration. Kousaku Iwatsubo; Susumu Minamisawa; Takashi Tsunematsu; Masamichi Nakagome; Yoshiyuki Toya; James E. Tomlinson; Satoshi Umemura; Robert M. Scarborough; Daniel E. Levy; Yoshihiro Ishikawa;  Journal of Biological Chemistry, 2004, 279, 40938-40945.

Metal Coordination-Based Inhibitors of Adenylyl Cyclase:  Novel Potent P-Site Antagonists.  Daniel E. Levy; Ming Bao; Diana B. Cherbavaz; James E. Tomlinson; David M. Sedlock; Charles J. Homcy; Robert M. Scarborough;  Journal of Medicinal Chemistry, 2003, 46, 2177-2186.

Hydroxamate Based Inhibitors of Adenylyl Cyclase (II):  the Effect of Cyclic Linkers on P-Site Binding.  Daniel E. Levy; Ming Bao; Jim Tomlinson; Robert M. Scarborough;  Bioorganic and Medicinal Chemistry Letters, 2002, 12, 3089-3092.

Hydroxamate Based Inhibitors of Adenylyl Cyclase (I):  the Effect of Acyclic Linkers on P-Site Binding.  Daniel E. Levy; Charles Marlowe; Kim Kane-Maguire; Ming Bao; Diana Cherbavaz; Jim Tomlinson; David Sedlock; Robert M. Scarborough; Bioorganic and Medicinal Chemistry Letters, 2002, 12, 3085-3088.

Arterial Repair After Stenting and the Effects of GM6001, a MMP Inhibitor.  Chris Li; Warren J. Cantor; Nafiseh Nili; Ranga Robinson; Louis Fenkall; Yen Le Tran; Heather A. Whittingham; Winston Tsui; Asim N. Cheema; John D. Sparkes; Kenneth Pritzker; Daniel E. Levy; Bradley H. Strauss; Journal of the American College of Cardiology, 2002, 39, 1852-1858.

Matrix Metalloproteinase Inhibitors:  A Structure Activity Study.  Daniel E. Levy; France Lapierre; Weisheng Liang; Wenqing Ye; Christopher W. Lange; Xiaoyuan Li; Damian Grobelny; Marie Casabonne; David Tyrrell; Kevin Holme; Alex Nadzan; Richard E. Galardy;  Journal of Medicinal Chemistry, 1998, 41(2), 199-223.

Matrix Metalloproteinase Inhibitor Drugs.  Daniel E. Levy; Alan M. Ezrin; Emerging Drugs:  The Prospects for Improved Medicines, 1997, 2, 205-230.

Matrix Metalloproteinase Inhibitors Reduce Phorbol Ester Induced Cutaneous Inflammation and Hyperplasia.  Walter Holleran; Richard E. Galardy; Wen Ni Gao; Daniel Levy; Peng Cho Tang; Peter M. Elias;  Archives of Dermatological Research, 1997, 289(3), 138-144.

In-Vivo Collagen Turnover Following Experimental Balloon Angioplasty Injury and the Role of Matrix Metalloproteinases.  Bradley H. Strauss; Ranga Robinson; Robert J. Chisholm; Grama Ravi; Madhu K. Natarajan; Shamir R. Mehta; Daniel E. Levy; Alan M. Ezrin; Richard A. Logan; Fred W. Keeley;  Circulation Research, 1996, 79 (3), 541-550.

Glycomimetics as Selectin Inhibitors.  John H. Musser; Mark B. Anderson; Daniel E. Levy; Current Pharmaceutical Design, 1995, 1, 221-232.

A Hydroxamic Acid Matrix Metalloprotease Inhibitor Blocks the Activity of Endothelin Converting Enzyme in Anesthetized Rats.  Daniel E. Levy; Peng Cho Tang; Keri Sweet; Brent Summers; France LaPierre; Alan M. Ezrin; Med. Chem. Res.  1994, 4, 547-553.

Synthesis of Novel Fused Ring C-Glycosides.  Daniel E. Levy; Falguni Dasgupta; Peng Cho Tang; Tetrahedron Asymmetry  1994, 5, 2265-2268, Invited Contribution.

Cell Adhesion and Carbohydrates.  Daniel E. Levy; Peng Cho Tang; John H. Musser; Annual Reports in Medicinal Chemistry  1994, 29, 215-224, Invited Contribution.

Towards the Synthesis of Calyculin:  A Synthetic Intermediate Corresponding to the C(26)-C(37) Fragment.  Henry A. Vaccaro; Daniel E. Levy; Akiyoshi Sawabe; Thomas Jaetsch; Satoru Masamune;  Tetrahedron Let. 1992, 33, 1937-1940.

Spectroscopic Determination of the Second Dissociation Constant of H2Se and the Activity Coefficients and Spectral Shifts of Its Ions.  Daniel E. Levy; Rollie J. Myers; J. Phys. Chem. 1990, 94, 7842-7847.












Copyright Daniel E. Levy, All Rights Reserved